3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
19
Carcinoma, Non-Small-Cell Lung
19
Breast Neoplasms
17
Lung Neoplasms
15
Colonic Neoplasms
11
Head and Neck Neoplasms
9
Rectal Neoplasms
7
Glioblastoma
5
Prostatic Neoplasms
4
Precancerous Conditions
4
Mouth Neoplasms
4
Esophageal Neoplasms
4
Central Nervous System Neoplasms
4
Adenomatous Polyposis Coli
4
Uterine Cervical Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Sarcoma
3
Neuroblastoma
3
Neoplasms
3
Liver Neoplasms
3
Gliosarcoma
3
Glioma
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Smoking
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Oropharyngeal Neoplasms
2
Nasopharyngeal Neoplasms
2
Multiple Myeloma
2
Interventions
Gemcitabine
7
Leucovorin
6
Irinotecan
6
Fluorouracil
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Capecitabine
4
Paclitaxel
3
Oxaliplatin
3
Ocoxin
3
Bevacizumab
3
pembrolizumab
2
entinostat
2
Sorafenib
2
Imatinib Mesylate
2
Everolimus
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
pralsetinib
1
palbociclib
1
irinotecan sucrosofate
1
halofantrine
1
guadecitabine
1
fludarabine
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Digestive System Neoplasms
×
Celecoxib
×
Clear all
NCT00808743
2013-05-16
PreDuoFAP
Radboud University Medical Center
Phase 2/3
Completed
37 enrolled